)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Evofem Biosciences (EVFM) investor relations material
Evofem Biosciences Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Net sales increased 10% year-over-year to $5.0 million in Q3 2025, driven by higher PHEXX unit sales and a full quarter of SOLOSEC sales, with SOLOSEC acquired in July 2024 and relaunched in November 2024.
Operating income reached $1.0 million, reversing a $2.4 million operating loss in the prior year quarter.
PHEXX net sales have grown each year since launch in 2020; SOLOSEC is expected to benefit from existing infrastructure and is being advanced for international approval.
The company terminated its planned merger with Aditxt in October 2025 after shareholder disapproval and is now pursuing re-listing and new fundraising.
Operating expenses declined 42% year-over-year, aided by a $1.9 million one-time gain from a change in contingent royalty liability accounting.
Financial highlights
Net product sales for Q3 2025 were $5.0M, up from $4.5M in Q3 2024, driven by SOLOSEC and a PHEXX price increase.
Net loss attributable to common stockholders for Q3 2025 was $1.7M ($0.01 per share), improved from $2.4M ($0.02 per share) in Q3 2024.
For the nine months ended September 30, 2025, net product sales were $10.62M, down 13% year-over-year due to lower PHEXX volume, partially offset by SOLOSEC sales.
Q3 2025 included a $1.93M one-time gain from reversal of previously accrued Rush Royalty liability.
Restricted cash as of September 30, 2025, was $0.8M, all restricted.
Outlook and guidance
Management plans to drive growth through expanded product access, new partnerships, and additional funding.
Cost of goods sold reduction initiatives are expected to increase per-unit profit and support entry into price-sensitive global markets.
Ongoing clinical trial for SOLOSEC may support future product positioning and cost-effectiveness claims.
The company expects to continue incurring net losses and negative cash flows for the foreseeable future.
Liquidity resources as of September 30, 2025, are insufficient to fund operations for the next 12 months; substantial doubt exists about the ability to continue as a going concern.
Operating income sustainability ex-one-time gains
Post-merger termination capital strategy
Quantify COGS reduction impact on future margins
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Evofem Biosciences earnings date
Q4 202524 Mar, 2026
Next Evofem Biosciences earnings date
Q4 202524 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Evofem Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage